SAN DIEGO, July 22, 2019 /PRNewswire/ -- Biocept,
Inc. (NASDAQ: BIOC), a leading commercial provider of liquid
biopsy tests designed to provide physicians with clinically
actionable information to improve the outcomes of patients
diagnosed with cancer, announces that it has entered into a
Laboratory Services Provider Agreement with Beacon Laboratory
Benefit Solutions, Inc. (BeaconLBS®), a nationally recognized
premier provider of laboratory benefit management technology
solutions to health and managed care companies in the United States. BeaconLBS administers
laboratory benefit management programs for health plans to improve
test ordering efficiency, test appropriateness, affordability, and
quality of care for health plan members. To better serve the needs
of physicians and patients, BeaconLBS connects them to its
Labs-of-Choice™, which are preferred, high-quality laboratories,
now including Biocept.
"We are very pleased to become a laboratory services provider
for BeaconLBS, which offers innovative laboratory management
technology solutions that benefit physicians, patients and payers,"
said Michael Nall, Biocept's
President and Chief Executive Officer. "As a BeaconLBS
Lab-of-Choice, more patients will have an opportunity to benefit
from our liquid biopsy testing platforms, which can help physicians
identify actionable biomarkers in patients diagnosed with cancer
and design personalized treatment programs in order to improve
outcomes."
About Biocept
Biocept, Inc. is a molecular diagnostics company with
commercialized assays for lung, breast, gastric, colorectal and
prostate cancers, and melanoma. The Company uses its proprietary
liquid biopsy technology to provide physicians with information for
treating and monitoring patients diagnosed with cancer. The
Company's patented Target Selector™ liquid biopsy technology
platform captures and analyzes tumor-associated molecular markers
in both circulating tumor cells (CTCs) and in plasma (ctDNA). With
thousands of tests performed, the platform has demonstrated the
ability to identify cancer mutations and alterations to inform
physicians about a patient's disease and therapeutic options. For
additional information, please visit www.biocept.com.
Forward-Looking Statements Disclaimer Statement
This release contains forward-looking statements that are based
upon current expectations or beliefs, as well as a number of
assumptions about future events. Although we believe that the
expectations reflected in the forward-looking statements and the
assumptions upon which they are based are reasonable, we can give
no assurance that such expectations and assumptions will prove to
have been correct. Forward-looking statements are generally
identifiable by the use of words like "may," "will," "should,"
"could," "expect," "anticipate," "estimate," "believe," "intend,"
or "project" or the negative of these words or other variations on
these words or comparable terminology. To the extent that
statements in this release are not strictly historical, including
without limitation statements as to the expansion in the number of
patients that will have an opportunity to benefit from our liquid
biopsy testing platforms, our ability to improve the outcomes
of patients diagnosed with cancer, and the potential clinical
utility of our proprietary technology platform, such
statements are forward-looking, and are made pursuant to the safe
harbor provisions of the Private Securities Litigation Reform Act
of 1995. The reader is cautioned not to put undue reliance on these
forward-looking statements, as these statements are subject to
numerous risk factors as set forth in our Securities and Exchange
Commission (SEC) filings. The effects of such risks and
uncertainties could cause actual results to differ materially from
the forward-looking statements contained in this release. We do not
plan to update any such forward-looking statements and expressly
disclaim any duty to update the information contained in this press
release except as required by law. Readers are advised to review
our filings with the SEC, which can be accessed over the Internet
at the SEC's website located at www.sec.gov.
Contact:
LHA Investor Relations
Jody Cain
Jcain@lhai.com
310-691-7100
View original content to download
multimedia:http://www.prnewswire.com/news-releases/biocept-announces-laboratory-services-provider-agreement-with-beaconlbs-300888259.html
SOURCE Biocept, Inc.